Drug developer Belite Bio falls on planned equity raise
U.S. STOCKS ON THE MOVE-Walt Disney, BankUnited, copper miners
U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources
U.S. STOCKS ON THE MOVE-Barrick Mining, Tesla, Accenture
Belite Bio surges after eye drug meets main goal in late-stage study
Brief: Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of Tinlarebant
Belite Bio's drug for genetic eye disease meets main goal in late-stage trial (updated)
Belite Bio's drug for genetic eye disease meets main goal in late-stage trial
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
U.S. RESEARCH ROUNDUP- Floor & Decor Holdings, Composecure, Outfront Media Inc
Belite Bio Q3 net loss widens on higher R&D expenses
Brief: Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant
Brief: Belite Bio Announces China NMPA Agrees To New Drug Application With Priority Review Based On Interim Analysis Results For The Treatment Of Stargardt Disease With Tinlarebant
Brief: Belite Bio Secures Up to $275M in Upsized Private Placement
Belite Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Belite Bio's Q2 net loss widens on higher R&D expenses
Belite Bio Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Belite Bio Announces Registered Direct Offering Of $15 Million
Brief: Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease